Announced
Financials
Tags
Friendly
Private Equity
Cayman Islands
Public
Pharmaceuticals
Cross Border
Pending
drug discovery
Acquisition
Minority
Single Bidder
Synopsis
Hillhouse Capital, a global Asia-focused private equity firm, agreed to invest £176m in Genscript Biotech-backed Probio Cayman, an antibody drug discovery company. The proceeds from the investment are intended to be used to satisfy the capital expenditure and other general working capital needs in the operation of the main business of Probio Cayman. The capital would provide an additional source of funding for the plan to build up the good manufacturing practice manufacturing capacity and the research and development capabilities of Probio Cayman to develop its existing business.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.